Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2CNS 1

Conditions

Glioblastoma 21Brain Neoplasms 10Medulloblastoma 7Glioma 7Central Nervous System Neoplasms 7Lymphoma 6Astrocytoma 5Oligodendroglioma 4Recurrence 3Gliosarcoma 3Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myeloid, Acute 2Ependymoma 2Burkitt Lymphoma 2Uveal Melanoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Newly Diagnosed High Grade Glioma 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, AIDS-Related 1Lung Neoplasms 1Intraocular Lymphoma 1Familial ependymoma 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21Specimen Handling 20CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Melanoma × Lomustine × Clear all
NCT00527657 2018-11-14

Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients

M.D. Anderson Cancer Center

Phase 1 Completed
17 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT00072345 2013-01-18

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡